Milo Biotechnology gets patent for muscular dystrophy treatment

Story excerpt provided by Crain’s Cleveland Business.

Written by Rachel Abbey McCafferty and Chuck Soder.

Milo Biotechnology has received a patent on an experimental gene therapy designed to reverse muscular dystrophy.

The Cleveland company received a parent patent for “Myostatin Inhibition for Enhancing Muscle and/or Improving Muscle Function.”

Click here to read the complete article.

Originally published December 4, 2014.